Following a significant pullback, NetEase (SEHK: 9999) shares are trading at levels that some analysts deem undervalued. We examine the financial models, peer comparisons, and the broader sector headwinds facing the Chinese gaming giant to assess if the current price presents a strategic entry point for long-term investors.
Investor appetite for hedge funds hits a record high, with quantitative and discretionary macro strategies leading demand. New data reveals these approaches captured over 70% of industry inflows last year, as allocators seek diversification and uncorrelated returns.
With interest rates, perks, and switching bonuses in constant flux, choosing the right current account is more complex than ever. Our guide cuts through the noise to help you secure the best deal for your everyday banking.
Investors in U.S. spot Bitcoin ETFs are holding significant paper losses on average, sparking concerns that a wave of redemptions could intensify the cryptocurrency's recent downturn.
Strong current earnings don't always signal a bright future. We examine three companies with solid margins but questionable long-term prospects in a shifting market landscape.
Under Armour faces a pivotal moment as a significant insider purchase coincides with a high-stakes legal loss and the exit of its Chief Product Officer, testing investor confidence in the embattled sportswear brand's turnaround strategy.
Applied Digital is making a decisive pivot from cryptocurrency mining to high-performance AI data center infrastructure, securing major long-term leases and breaking ground on a new campus designed for large-scale AI workloads, as demand for specialized compute power surges.
BitMine Immersion Technologies (NYSEAM:BMNR) is navigating a turbulent period marked by over $6 billion in unrealized losses from its concentrated Ethereum holdings and the abrupt departure of its president. The company's aggressive crypto treasury strategy and governance decisions are now under the microscope.
Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
While Tesla's stock remains resilient, the promise of a self-driving future presents both staggering potential and significant hurdles for investors to consider.
A deep dive into the conflicting signals from Church & Dwight's stock valuation. While a discounted cash flow model suggests a significant discount, its premium P/E ratio tells a different story, leaving investors to weigh pricing power against market expectations.
Shares of Empire State Realty Trust (ESRT) are trading at $6.63, presenting investors with a conundrum: a narrative suggesting undervaluation clashes with a premium price-to-earnings multiple. We examine the divergence and what it means for the iconic property owner.
A new valuation model suggests Eos Energy Enterprises' stock could be significantly undervalued, presenting a potential opportunity for investors amid a shifting energy policy landscape.
As Li Auto's stock languishes near 52-week lows, a deep dive into its valuation metrics suggests the electric vehicle maker may be oversold. With shares trading at a significant discount to intrinsic value estimates, analysts debate whether this is a moment of crisis or a potential buying window.
VEON is deepening its investment in Uzbekistan's digital economy with a new network operations center for Beeline and the launch of BuildX, a software and AI development unit. The moves signal a strategic pivot from traditional telecom services towards higher-margin digital offerings in Central Asia.
Ondas Holdings advances its defense sector ambitions as its Optimus drone gains Blue List status for expedited U.S. procurement, while formally launching its defense and security division at the Singapore Airshow. The strategic moves come as the company's stock, after significant long-term gains, faces recent pressure, testing investor patience for tangible contract wins.
A deep-dive valuation analysis using a two-stage discounted cash flow model suggests Cadence's current share price may be trading at a premium to its intrinsic value, raising questions for investors in the critical EDA sector.
Amidst a cautiously optimistic economic backdrop in Europe, we examine three publicly traded companies with market capitalizations exceeding €30 million that combine the growth potential of small-caps with notable financial resilience.
With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.
A woman identifying herself as Justin Sun's former partner has leveled serious market manipulation claims against the Tron founder, alleging he used employee-linked Binance accounts to inflate TRX's price during the 2017-2018 crypto boom before cashing out, leaving retail investors holding the bag.
